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ABSTRACT 
The pathomechanism of Alzheimer’s disease (AD) certainly involves mitochondrial 
disturbances, glutamate excitotoxicity, and neuroinflammation. The three main aspects of 
mitochondrial dysfunction in AD, i.e., the defects in dynamics, altered bioenergetics, and the 
deficient transport act synergistically. In addition, glutamatergic neurotransmission is affected 
in several ways. The balance between synaptic and extrasynaptic glutamatergic transmission 
is shifted toward the extrasynaptic site contributing to glutamate excitotoxicity, a 
phenomenon augmented by increased glutamate release and decreased glutamate uptake. 
Neuroinflammation in AD is predominantly linked to central players of the innate immune 
system, with central nervous system (CNS)-resident microglia, astroglia, and perivascular 
macrophages having been implicated at the cellular level. Several abnormalities have been 
described regarding the activation of certain steps of the kynurenine (KYN) pathway of 
tryptophan metabolism in AD. First of all, the activation of indolamine 2,3-dioxygenase, the 
first and rate-limiting step of the pathway, is well-demonstrated. 3-Hydroxy-L-KYN and its 
metabolite, 3-hydroxy-anthranilic acid have pro-oxidant, antioxidant, and potent 
immunomodulatory features, giving relevance to their alterations in AD. Another metabolite, 
quinolinic acid, has been demonstrated to be neurotoxic, promoting glutamate excitotoxicity, 
reactive oxygen species production, lipid peroxidation, and microglial neuroinflammation, 
and its abundant presence in AD pathologies has been demonstrated. Finally, the 
neuroprotective metabolite, kynurenic acid, has been associated with antagonistic effects at 
glutamate receptors, free radical scavenging, and immunomodulation, giving rise to potential 
therapeutic implications. This review presents the multiple connections of KYN pathway-
related alterations to three main domains of AD pathomechanism, such as mitochondrial 
dysfunction, excitotoxicity, and neuroinflammation, implicating possible therapeutic options. 
 
 3 
Keywords: Alzheimer’s disease, mitochondrial dysfunction, glutamate excitotoxicity, 
neuroinflammation, tryptophan metabolism, kynurenine pathway, kynurenic acid, 3-hydroxy-
L-kynurenine, quinolinic acid 
  
 4 
1. INTRODUCTION 
Alzheimer’s disease (AD) is the most prevalent progressive neurodegenerative disorder, 
characterized by age-related memory impairments and personality changes, placing a 
significant burden not only on the families and caregivers, but on the global economy as well 
[1]. As a result of the great scientific effort which was made to reveal the complex 
pathomechanism of AD, the deleterious factors responsible for disease development are 
becoming better understood [2]. However, currently only symptomatic therapies are available 
for this insidious condition, and there is at present no curative treatment available [3]. 
Accordingly, there is a huge need for the identification of novel therapeutic targets via which 
a better symptomatic or causative care may be provided beside the more widely applied 
preventive measures. A number of hypotheses exist with regard to the pathogenesis of 
AD. In addition to the probably most popular amyloid cascade and tau hypotheses, some 
alternative ones, such as those related to DNA damage, aberrant neuronal cell cycle re-
entry, and demyelination, have been elaborated to explain certain discrepancies in the 
current models and the serial failure of clinical trials assessing drugs targeting amyloid- 
or tau-induced alterations, and to try to fill the remaining gaps [4]. However, the 
pathological hallmarks currently applied to establish the definite diagnosis of AD during 
autopsies are amyloid plaques and neurofibrillary tangles, keeping in mind that the 
exact initiating factor in AD pathogenesis still remains unknown. Despite the mostly 
unknown initiating factor, downstream mitochondrial disturbances, glutamate 
excitotoxicity, and neuroinflammation serve as probably the most important linking 
points in neurodegenerative disorders, being demonstrated in human and experimental 
studies in AD as well, in addition to the distinguishing proteinopathic features of 
neurodegenerative conditions. Some metabolites and enzymes of the kynurenine (KYN) 
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pathway of tryptophan (TRP) metabolism have come into focus of recent research with 
regard to these three cardinal aspects of neurodegeneration [5]. 
The aim of this review is to highlight some aspects of mitochondrial disturbances, glutamate 
excitotoxicity, and neuroinflammation and their relations to the multiple documented 
alterations of the KYN pathway of the TRP metabolism (Fig. 1) in AD and its experimental 
models, with the delineation of some possible therapeutic targets, without attempting an in-
depth analysis of current leading and alternative hypotheses of AD, an effort exceeding 
the scope of this current paper. 
 
2. MITOCHONDRIAL DISTURBANCES IN ALZHEIMER’S DISEASE 
There are three main aspects of mitochondrial dysfunction in AD: 1) defects in mitochondrial 
fission/fusion (i.e., dynamics); 2, altered mitochondrial bioenergetics; and 3) defects in 
mitochondrial transport [6-8]. 
Mitochondrial dynamics is a process consisting of fusion (a moving mitochondrion interacts 
with a passive one forming a tubular network) and consecutive fission (a segmentation 
resulting in two mitochondria) [9, 10]. Fusion is mediated by mitochondrial inner membrane 
GTPases optic atrophy 1 (Opa1) and mitofusin 1 and 2 (Mfn1 and Mfn2), whereas fission is 
regulated by mitochondrial outer membrane division proteins dynamin-related protein 1 
(Drp1) and mitochondrial fission protein 1 (Fis1) amongst others. The analysis of brain 
samples of AD patients demonstrated fragmented and punctuated mitochondrial morphology 
resulting from dysfunctional mitochondrial dynamics [11, 12]. Accordingly, the mRNA levels 
of Fis1 were increased, whereas those of Opa1, Mfn1, Mfn2, and surprisingly Drp1 were 
decreased in AD brains [13]. In vitro studies, where M17 or N2a cells overexpressing the 
wild-type amyloid-beta (Aβ) precursor protein (AβPP) or that of comprising the Swedish 
mutation (AβPPsw) were applied, demonstrated that Aβ accumulation resulted in decreased 
 6 
Mfn1, Mfn2 and Opa1, whereas Fis1 levels were increased, accompanied with the 
fragmentation of mitochondria and reduction in their number [12, 14]. Alterations in the level 
of Drp1 are controversial, because it was demonstrated to be unchanged or interestingly 
decreased [12, 14]. The fragmentation of mitochondria was also confirmed in neuronal cell 
cultures obtained from a transgenic (Tg2576) mouse model of AD, where Fis1 gene and 
protein were significantly upregulated, whereas Mfn1 gene and protein were decreased [15]. 
Furthermore, the application of oligomeric Aβ-derived diffusible ligands (ADDL) induced the 
decrease of mitochondrial length and reduced mitochondrial density in neurites and axons via 
the impairment of their bidirectional transport [16-18]. The underlying reason for Aβ-induced 
mitochondrial alterations may be the presence of direct interaction of Aβ aggregates with 
these organelles, followed by their accumulation related to translocase of outer membrane 40 
(TOM40) and translocase of inner membrane 23 (TIM23) [19-21]. This pathological Aβ 
accumulation blocks the import of cytoplasmic proteins into the mitochondria, interfering 
with their functionality, and its extent was linked to the degree of cognitive impairment of AD 
[21, 22]. One aspect of this impaired functionality may be the interaction of Aβ with Drp1 
[23]. In a mouse model of AD, the observed association of Aβ with synaptic mitochondria 
may serve as one of the culprits for synaptic degeneration characteristic of AD [18]. In 
addition to Aβ-related impairment in mitochondrial dynamics, tau may also have a 
pathological influence on it [24, 25]. Accordingly, the co-localization of hyperphosphorylated 
tau protein with Drp1 was demonstrated as well with the presence of excessive mitochondrial 
fragmentation [26]. 
In addition to its effect on mitochondrial dynamics, the binding of Aβ to the mitochondria 
results in deficient energy production as well, considerably contributing to the pathogenesis of 
AD [27, 28]. The assessment of mitochondria isolated from brain specimens of AD patients 
demonstrated the reduced activity of cytochrome c oxidase (i.e., complex IV of the electron 
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transport chain (ETC)) and ATP synthase (i.e., complex V of the ETC), with a compensatory 
increased expression of the corresponding genes [29-33]. Furthermore, the reduced activity of 
key mitochondrial matrix enzymes, such as pyruvate dehydrogenase and α-ketoglutarate 
dehydrogenase was demonstrated as well [34-36]. The presence of alterations in 
mitochondrial bioenergetics was clearly detected in in vitro or in vivo models overexpressing 
AβPP or AβPPsw with or without mutations in the presenilin 1 (PS1) or presenilin 2 (PS2) or 
tau genes [12, 27, 37-47]. In addition to enzymatic dysfunction, oxidative stress-induced 
damage of mitochondrial DNA (mtDNA) is pronounced as well, and accordingly, the post 
mortem analysis of the brains of AD patients demonstrated increased rate of mtDNA 
mutations and decreased mtDNA copy number [48-51]. The exposure of mitochondria to 
different Aβ species and their accumulation resulted in impaired activity of the ETC with a 
consequent decrease in respiration rates and mitochondrial membrane potential and an 
increase in reactive oxygen species (ROS) production [39, 52-56]. The pathological 
interactions involve the inhibition of Aβ-binding alcohol dehydrogenase (ABAD), the 
decrease of the threshold of mitochondrial permeability transition pore (mPTP) formation by 
cyclophilin D, and the increased conductivity of the voltage-dependent anion-selective 
channel 1 as well, thereby considerably contributing to the further worsening of mitochondrial 
dysfunction [57-59]. The presence of apoptosis-related events (e.g., mitochondrial swelling, 
opening of the mPTP, cytochrome c release, and caspase-3 activation) was demonstrated as 
well [60-63]. The Aβ-induced ROS production may evoke a vicious cycle via the further 
enhancing Aβ formation [45, 64]. ROS generation resulted in the upregulation of beta-site 
amyloid precursor protein cleaving enzyme 1 (BACE1) activity and expression level, thereby 
increasing Aβ load [65-67]. Beside the deleterious effects of Aβ, the pathological forms of tau 
induce the disturbance of mitochondrial bioenergetics as well. Studies with cell lines or 
transgenic animals overexpressing mutant tau protein demonstrated mitochondrial 
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depolarization, impaired respiration, reduced ATP synthesis, increased oxidative stress, and 
lipid peroxidation [25, 27, 41, 44, 47, 68, 69]. Interestingly, mitochondrial energy 
disturbances probably precede Aβ-related pathology [27, 43]. In light of proteomic analyses, 
these abnormalities may be related to the alterations of complexes I and IV of the ETC; the 
impairment of the former one was related to tau, whereas the impairment of the latter one was 
related to Aβ [27]. This second aspect of mitochondrial disturbance in AD accompanies to 
synaptic dysfunction as well, as preserved bioenergetics are essential for the following 
functions: 1) the maintenance of ion gradients required for sustained membrane potential; 2) 
the mobilization and release of synaptic vesicles; and 3) the support of synaptic assembly and 
plasticity [8]. 
The presence of APOE ε4 genotype has been demonstrated to be associated with a 
considerably (i.e., four times) enhanced likelihood for the development of AD [70]. APOE ε4 
contributes to the pathogenic processes by disrupting neurogenesis, cholesterol metabolism, 
AβPP processing, the degradation of Aβ, tau hyperphosphorylation, and other cellular 
pathways, including mitochondrial function and synaptic plasticity [70-73]. The decreased 
activity of α-ketoglutarate dehydrogenase in AD brain correlates with APOE ε4 genotype and 
it decreases the expression of complex I and IV and the activity of complex IV of the ETC as 
well [74, 75]. This impairment is presumably mediated by the interaction of APOE ε4 with 
mitochondria [75, 76]. 
The transport of mitochondria is mediated by fast axonal transport [77]. Kinesin-1 heavy 
chain protein, encoded by the KIF5B gene is responsible for the anterograde transport of 
mitochondria with the aid of adaptors (trafficking kinesin-binding protein 1 and 2; Trak1 and 
Trak2) to mitochondrial Rho GTPase 1 and 2 (Miro1 and Miro2), whereas dynein protein 
performs their retrograde transport via the interaction with the dynactin complex [78]. The 
treatment of rodent hippocampal neurons with Aβ or the presence of a PS1 or AβPP mutation 
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resulted in the significant reduction of anterograde mitochondrial transport, thereby 
considerably accompanying to synaptic dysfunction characteristic of AD, which findings 
were confirmed in mouse model of AD and by the post mortem analysis of brains from AD 
patients [15, 79-86]. It was hypothesized that alterations in synaptic mitochondria develops 
earlier than in non-synaptic mitochondria [87]. It seems that tau is required for Aβ-induced 
impairment of axonal transport, which process is presumably initiated via the activation of 
NMDARs, glycogen synthase kinase 3β (GSK3β), and casein kinase 2 (CK2) [84, 88, 89]. 
Naturally, the above detailed three main aspects of mitochondrial dysfunction act 
synergistically: the activation of Drp1 and Fis1 by free radicals resulted in mitochondrial 
fragmentation, their altered synaptic transport, and consequentially reduced synaptic ATP 
levels and dysfunction [87]. Furthermore, in light of the downregulation of peroxisome 
proliferator-activated receptor gamma (PPARγ) coactivator 1-alpha (PGC-1α) and its target 
genes, the mitochondrial biogenesis signaling has been indicated to be impaired as well in AD 
[90, 91]. 
 
3. GLUTAMATE EXCITOTOXICITY IN ALZHEIMER’S DISEASE 
Beside and in part in connection with mitochondrial dysfunction, Aβ can influence 
glutamatergic neurotransmission in several ways. Under physiological concentrations, Aβ 
takes part in the regulation of proper neurotransmitter release; however, the elevated 
concentrations of Aβ alters synaptic transmission via its deteriorating effects on synaptic 
vesicle pools [92, 93]. With regard to its effects on glutamatergic neurotransmitter receptors, 
the NMDAR may be the major site of Aβ action even in the early stages of AD; and 
furthermore, NMDAR activation increase the production of Aβ [94]. The composition of a 
conventional NMDAR is composed of two glycine or D-serine-binding GluN1 subunits, 
which are responsible for the formation of the ion channel, and two glutamate-binding GluN2 
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(A-D) subunits, having regulatory and refining roles. The available data suggest that the 
predominance of GluN2A subunit-containing NMDARs at the synaptic site promotes 
neuronal survival, involving the activation cyclic-AMP response element binding protein 
(CREB) and the suppression of forehead box protein O (FOXO)-mediated pathways [95-99]. 
Contrastingly, the predominance of GluN2B subunit-containing NMDARs at the 
extrasynaptic site, increased by the phosphorylation at Tyr1336 site, mediates neurotoxicity 
involving the opposite effects on the above mentioned pathways [95-99]. However, in light of 
some recent findings, the simultaneous activation of synaptic NMDARs may be also 
necessary for the initiation of cell death program [100]. So in brief, alterations in synaptic and 
extrasynaptic glutamatergic transmissions seem to synergistically contribute to the 
pathomechanism of AD. The alterations induced by oligomeric Aβ contributing to synaptic 
dysfunction involve the decrease of long-term potentiation (LTP; a form of synaptic 
strengthening following a brief, high-frequency stimulation), the enhancement of long-term 
depression (LTD; a form of synaptic weakening following low-frequency stimulation or 
synaptic inactivity), and the depotentiation of LTP [101-104]. The enhancement of LTD in 
AD is mediated by the internalization of synaptic α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) and NMDA receptors induced by oligomeric Aβ and non-
apoptotic caspase activation [62, 105, 106]. In vitro studies suggest that the activation 
NMDARs by Aβ is mainly confined to those containing GluN2B subunit, i.e., with a 
preferential localization at the extrasynaptic site [107]. Furthermore, the experimental 
intracerebroventricular injection of Aβ in rats downregulated the ratio of GluN2A/GluN2B 
subunits, shifting the pathways toward excitotoxicity [99]. Some of the deleterious 
downstream excitotoxic effects of Aβ via the GluN2B subunit-containing NMDARs is 
mediated by the connection of the receptors to neuronal nitric oxide (NO) synthase (NOS) by 
a scaffolding protein PSD-95 (postsynaptic density protein of molecular weight 95 kDa), 
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thereby increasing the production of NO in an excessive amount [108-110]. The above 
mentioned increase in the production of Aβ via extrasynaptic NMDAR activation is probably 
mediated by the shift of AβPP production from AβPP695 to Kunitz protease inhibitory 
domain-containing isoforms with higher amyloidogenic potential and leads to the formation 
of a vicious cycle [111, 112]. GluN2B-mediated glutamatergic neurotransmission seems to be 
involved in tau-induced neurotoxicity as well, probably via the tyrosine kinase Fyn pathway 
[113, 114]. Tau increased targeting of Fyn sensitizes NMDARs to Aβ toxicity with a positive 
feedback, i.e., the Aβ-triggered hyperphosphorylation of tau enhance its affinity for Fyn 
[115]. The major downstream pathological effect evoked by Aβ in this way may be the 
disturbance of neuronal calcium homeostasis [116]. 
In addition to its receptorial effects, Aβ downregulates glutamate uptake capacity of 
astrocytes and thereby induces a dysfunctional glutamate clearance from the extracellular 
space [117-120]. Indeed, soluble Aβ oligomers were proved to be capable of inducing 
glutamate release from astrocytes [121]. The downregulation of the expression of excitatory 
amino acid transporter 2, one of the transporters responsible for glutamate uptake by 
astrocytes, was demonstrated in transgenic mouse models as well [122, 123]. However, the 
available data on human specimens with regard to this issue are controversial [124-127]. 
Additionally, some findings indicate that microglial upregulation of cystine/glutamate 
antiporter system xc
- may also contribute to altered glutamate homeostasis [128]. The 
consequentially elevated glutamate levels in the extracellular space and the above delineated 
presence of energy impairment, as a consequence of mitochondrial dysfunction and oxidative 
stress, may interact to cause glutamate excitotoxicity, involving a partial membrane 
depolarization, which results in the relief of the Mg2+ blockade of the NMDAR channel and 
leads to subsequent calcium overload of the cell [129]. 
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4. NEUROINFLAMMATION IN ALZHEIMER’S DISEASE 
Emerging evidence supports that neuroinflammation, i.e., the active presence of 
proinflammatory immunological processes within the CNS, contributes substantially to the 
pathogenesis of a number of neurodegenerative disorders, including AD, and is probably 
more relevant in terms of the pathogenesis as core neuropathological hallmarks of the disease 
[130]. Signs indicative of ongoing neuroinflammation during the course may be present 
before the dementia stage, opening possibilities for the identification of putative prognostic 
biomarkers as well as of potential therapeutic targets of the disease. 
Pathogenic markers of neuroinflammation in AD include cellular and soluble factors as well. 
As compared with encephalitides and multiple sclerosis (MS) where the adaptive immune 
system with target-specific T and B lymphocytes are presumed to play key roles in disease 
pathogenesis (including the promotion of the degenerative alterations), neuroinflammation in 
neurodegenerative disorders including AD are predominantly linked to central players of the 
innate immune system, with CNS-resident microglia, astroglia, and perivascular macrophages 
having been heavily implicated at the cellular level [131]. This neuropathological dichotomy 
is reflected also by the findings of recent genome-wide association studies (GWASs) and an 
expression quantitative trait locus (eQTL) genetic study [132]. 
Microglia are resident myeloid cells of the CNS that, similarly to tissue macrophages, are 
responsible for screening their respective tissue region for pathogens and cellular debris in 
order to engage them in part via phagocytosis and degradation [133]. Furthermore, these cells 
are also involved in the development and maintenance of neuronal circuitry in part by 
releasing trophic factors such as brain-derived neurotrophic factor (BDNF) [134, 135]. There 
is a plethora of evidence for the crucial contribution of microglia to AD pathogenesis. 
Microglia are long known to be abundantly present around senile Aβ plaques in post mortem 
AD brain tissues [136]. These cells are phenotypically altered, suggestive of being reactive to 
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pathological stimuli. This increased microglial activation in the human brain with probable 
AD can now be reflected also by non-invasive imaging techniques taking advantage of 
radiotracers (such as microglial translocator protein (TSPO) ligands) used with positron 
emission tomography [137, 138]. Evidence suggests that brain parenchymal Aβ (especially in 
monomeric form) is capable of priming and thus aiding the activation of microglia in 
response to pathological stimuli, which in turn produce and release a number of 
proinflammatory cytokines and chemokines [131, 139-141]. This process is presumed to be 
aggravated by additional environmental and genetic components such as systemic 
inflammation and mutations affecting the innate immune system, respectively [131]. Though 
the in vivo relevance of microglial phagocytosis of Aβ is a matter of debate, microglia are 
known to express intra- and extracellular Aβ degrading enzymes (e.g., neprilysin and insulin-
degrading enzyme, respectively), and their normal function plays crucial roles in the clearance 
of parenchymal Aβ from the brain, most probably as part of a self-limiting adaptive process 
[142, 143]. The sustained presence of Aβ in the brain, however (especially in more 
aggregated forms, such as oligomers, protofibrils, and fibrils), is presumed to lead to 
permanent neuroinflammation with a chronic activation of microglia through various 
receptor-dependent and -independent mechanisms, which is accompanied by different 
microglial phenotypic alterations and deficient microglial function in a self-sustaining 
process, supposedly contributing to neurodegeneration and the development tau pathology in 
the AD brain [131]. In line with this concept, deficient microglial function has been 
demonstrated in transgenic AD mice, whereas mutations affecting genes involved in 
microglial phagocytosis and function, including TREM2, CD33, MS4A6A, and CR1, have 
been associated with an increased risk of sporadic AD, and the levels of the autophagy protein 
Beclin 1, with crucial roles in microglial phagocytosis, have been shown to be decreased in 
microglia isolated from brains of sporadic AD patients [144-154]. Though the applicability of 
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the ‘proinflammatory M1’ versus ‘anti-inflammatory M2’ dichotomous phenotypical 
classification of macrophages for CNS-resident microglia is extensively debated, agonists of 
PPARγ, a transcription factor that drives anti-inflammatory processes including a switch 
toward an M2 phenotype and whose relevance is of increasing interest in MS as well, are 
under extensive preclinical and clinical investigation as potential disease-modifying therapies 
in AD, with a phase 3 trial called TOMORROW currently ongoing with the PPARγ agonist, 
pioglitazone [131, 155-160]. 
Astroglia, a resident cell-type of the CNS of neurodectodermal origin, has been strongly 
implicated in the pathogenesis of AD, though the information at present available about its 
exact roles in the pathogenesis is substantially less comprehensive than about those of 
microglia. Similarly to microglia, reactive astrocytes surround and engage Aβ senile plaques, 
contributing to neuroinflammation via releasing cytokines, chemokines, and nitric oxide [130, 
161-163]. Just like microglia, astrocytes express intra- and extracellular Aβ-degrading 
enzymatic apparatus upon exposure to Aβ [164]. Furthermore, they also internalize and 
degrade Aβ, with astroglial ApoE playing crucial roles in both astroglia- and microglia-
mediated Aβ clearance among experimental conditions [165-168]. Supporting a potential 
detrimental role of astrocytes upon chronic activation during AD pathogenesis, viral 
inactivation of astrocytes alleviated the pathology in a transgenic murine model of AD [169]. 
The potential roles of other cell types in the CNS in the modulation of neuroinflammation in 
AD, including those of perivascular macrophages, endothelial cells, neurons, and 
oligodendrocytes, are also under investigation, but the results are at present far less conclusive 
compared to those for microglia and astrocytes [131]. 
Alterations indicative of ongoing neuroinflammation in AD can be detected at the level of 
soluble macromolecules as well. The expression of a number of proinflammatory cytokines, 
major sources of which are astrocytes and microglia, have been revealed in human AD brains, 
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as well as in the brains of transgenic rodent AD models [170-181]. The most frequently 
reported cytokines include tumor necrosis factor alpha (TNFα), interleukin (IL)-1β, IL-6, IL-
12, and IL-23 among many others. The possible biomarker value of the cerebrospinal fluid 
(CSF) or plasma levels of some of these cytokines have also been proposed in AD; however, 
the reports are extremely heterogeneous, which at present do not enable firm conclusions to 
be reached [182]. More intriguingly, the levels of some of the cytokines found elevated in the 
CSF of AD patients by some authors have also been reported to be increased even before the 
dementia phase of AD, i.e., during the stage of mild cognitive impairment (MCI) [182]. In 
particular, elevated levels of the proinflammatory cytokine, TNFα, and its soluble receptors, 
sTNFR1 and sTNFR2, in the CSF of patients with MCI were reported to predict more rapid 
conversion to AD dementia [183, 184]. Though these types of ‘conversion studies’ are 
associated with severe inherent limitations, they substantiate the potential diagnostic 
relevance of neuroinflammatory cytokine alterations in AD [185]. Despite the proposed and 
increasingly established roles of proinflammatory cytokine alterations in disease pathogenesis 
in AD, controversial results have also been published demonstrating deleterious effects of 
anti-inflammatory cytokines and beneficial effects of proinflammatory cytokines in terms of 
brain Aβ clearance in vivo [186-190]. Of note, generally disappointing results have been 
obtained from studies aiming at the modification of inflammatory response in AD with non-
steroidal anti-inflammatory drugs (NSAIDs) or elective cyclooxygenase-2 (COX-2) inhibitors 
at the clinical level [191-195]. These molecules in part aim at reducing the production of the 
inflammatory arachidonate metabolite prostaglandin E2, the level of which was likewise 
found altered in the CSF of AD patients and whose microglial receptorial action appears to be 
crucial in the development of core pathological features in AD animal models, whereas 
another presumed mechanism of action of NSAIDs is related to the activation of PPARγ [196-
200]. All these underlie the relevance of the double-edged nature of neuroinflammation in AD 
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and neurodegenerative conditions as a whole, a maladaptive chronification of an originally 
beneficial acute immune response, the suppression of which may result in adverse outcomes, 
and the exploitation of the therapeutic potential of which will definitely require further 
research and more sophisticated therapeutic approaches. 
 
5. THE RELATION OF KYNURENINES TO MITOCHONDRIAL DYSFUNCTION, 
GLUTAMATE EXCITOTOXICITY, AND NEUROINFLAMMATION, AND THEIR 
INVOLVEMENT IN THE PATHOGENESIS OF ALZHEIMER’S DISEASE 
Approximately 95% of TRP is metabolized through its KYN pathway (Fig. 1) [201]. 
This metabolic route consists of several neuroactive compounds, including kynurenic 
acid (KYNA), 3-hydroxy-L-KYN (3-OH-L-KYN), 3-hydroxyanthranilic acid (3-OH-
ANA), and quinolinic acid (QUIN). The detailed description of their physiological 
functions together with a historical overview of research on these metabolites have 
already been published, and are, accordingly, out of the scope of this current review 
[202]. Briefly, this pathway is predominantly responsible for the endogenous production 
of nicotinamide adenine dinucleotide, and is capable of influencing redox reactions and 
glutamatergic neurotransmission through its neuroactive intermediates, often in 
opposite directions. Although some other metabolites of the pathway may also have 
effects on neuronal function and dysfunction (especially in terms of redox reactions), 
their role in neuronal physiology and pathophysiology is at present less firmly 
established and are probably less important compared to the ‘neuroactive’ compounds 
[203]. A sustained balance between the concentrations of neuroactive intermediates of 
the KYN pathway may help to ensure the maintenance of normal neural function. By 
contrast, a number of abnormalities have been described as regards the activation of certain 
steps of the KYN pathway of TRP metabolism in various tissues and CNS regions in 
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neurodegenerative disorders, including AD (Figs. 2 and 3) [5, 202, 204-207]. Accordingly, 
therapeutic options may arise either via the application of drug analogs or via the modulation 
of the activity of their producing enzymes [5, 208-211]. 
 
Indolamine 2,3-dioxygenase 
As regards the first and rate-limiting step of the pathway, a number of studies described 
increased activity of indolamine 2,3-dioxygenase (IDO) in AD [212-215]. A group 
demonstrating increased activity of IDO in the serum of AD patient reported an inverse 
correlation of IDO activity with cognitive performance, accompanied by a positive 
correlations with the levels of neopterin, a macrophage activity marker, as well as soluble 
receptors for TNF and IL-2 [212, 213]. Others reported increased IDO immunoreactivity in 
microglia, astrocytes, and neurons, with the glial expression of IDO being the highest 
surrounding senile plaques [214]. The preferential accumulation of IDO in senile plaques as 
well as neurofibrillary tangles have later been confirmed by another group as well [216]. In 
line with these results and the proposed ability of Aβ to activate microglia in AD brains, 
increased IDO expression has been demonstrated in microglia and human primary 
macrophages in vitro upon exposure to Aβ1-42 [217]. These together indicate that the 
inflammatory milieu in AD, including elevated concentrations of TNFα, a potent activator of 
IDO, promotes the activation of TRP metabolism via the KYN pathway, leading to the 
production of multiple downstream effectors with various potential consequences relevant in 
terms of the pathogenesis of AD, as discussed below. 
 
3-Hydroxy-L-kynurenine and 3-hydroxyanthranilic acid 
According to some early studies, the proposed deleterious effects of 3-OH-L-KYN, a 
metabolite produced by kynurenine 3-monooxygenase (KMO), are mediated by free radicals 
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and not glutamate receptors, and some of its detrimental actions may be due to its metabolite, 
3-OH-ANA, via its auto-oxidation, leading to the production of superoxide anion [218-221]. 
In contrast, there is a body of evidence calling for antioxidant and free radical scavenging 
properties inherent to 3-OH-L-KYN as well; therefore, a dual action in the CNS may be 
proposed in this respect [222]. Indeed, in studies on striatal slices, 3-OH-L-KYN exerted a 
concentration- and time-dependent dual effect on lipid peroxidation, inducing pro-oxidant 
actions at low (5-20 μM) and antioxidant activity at higher (100 μM) micromolar 
concentrations [223]. The proposed protective actions were related to the stimulation of 
glutathione S-transferase and superoxide dismutase activities and to the elevations in the 
protein contents of the transcription factor and antioxidant regulator nuclear factor (erythroid-
derived 2)-like 2 (Nrf2) and some of its related proteins [223]. It is important to mention that 
the basal extracellular concentrations of 3-OH-L-KYN in the rat brain (2 nM) are far below 
the above mentioned levels [224]. A recent study assessing the effects of 3-OH-L-KYN and 
3-OH-ANA with regard to mitochondrial dysfunction demonstrated that both compounds 
decreased 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction in 
a concentration-dependent manner in association with an impairment of mitochondrial 
membrane potential [225]. However, these findings were not related to alterations in ROS 
production or lipid peroxidation, probably due to the demonstrated hydroxyl radical and 
peroxynitrite scavenging activities of both compounds [225]. Summarily, the concentration- 
and time-dependent toxic effects of 3-OH-L-KYN and 3-OH-ANA include the impairment of 
cellular energy metabolism, but the accompanying role of early ROS production is 
controversial. Nevertheless, these findings demonstrate that the KMO branch of the 
kynurenine pathway, i.e., which gives rise to the metabolites 3-OH-L-KYN and 3-OH-ANA 
among others, may represent a direct relationship between neuroinflammation and oxidative 
stress/mitochondrial dysfunction in AD, as this branch is preferentially active in 
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microglia/macrophages, which respond with IDO overexpression and subsequently increased 
KYN metabolism upon exposure to Aβ [217, 226-229]. 
With regard to the levels of these metabolites in AD tissues, though early studies 
demonstrated non-significant alterations in 3-OH-L-KYN levels in AD brains, recent 
immunohistochemical studies proved that 3-OH-L-KYN may considerably accompany to the 
damage of neuronal tissues, with its levels found to be significantly elevated in hippocampal 
neurons in AD compared to controls [216, 230, 231]. With regard to the periphery, markedly 
increased levels of 3-OH-L-KYN [232] as well as elevated levels of circulating IgA directed 
against 3-OH-L-KYN [233] were found in serum samples of AD patients, though a study 
found only a trend for 3-OH-L-KYN to be increased in the plasma of AD patients [234]. This 
elevation in the periphery may at least in part underlie the elevated concentrations of 3-OH-L-
KYN and its metabolite QUIN in AD brain tissues, as 3-OH-L-KYN can pass through the 
BBB via an active transport. In contrast, the CSF content of 3-OH-L-KYN in AD patients was 
found decreased by 81% [235]. 
The potential alteration of 3-OH-L-KYN and 3-OH-ANA levels in the brain may also 
be relevant in terms of neuroinflammation in AD, since both molecules have been associated 
with potent immunosuppressive features, as being among the most potent effectors of IDO-
mediated endogenous immunosuppression, an effect relevant in immunological phenomena 
such as allograft acceptance, tumor camouflage, and maternofetal tolerance [5]. Of note, these 
effects are generally attributed to the suppression of target-specific immunity, especially of 
Th1/Th17 cell proliferation, which is a response rather characteristic of MS than of AD where 
natural immunity is presumed to take leading roles. However, a recent report revealed that 
infiltrating Th1 and Th17 cells are present in the brain of transgenic AD mice (AβPP/PS1), 
and that Aβ-specific Th1 cells transferred to these murine brains could elicit marked 
microglial activation, Aβ deposition, and cognitive dysfunction [236]. Similar lymphocytic 
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engagement of deposited Aβ can be seen in a clinical and pathological subtype of cerebral Aβ 
angiopathy (CAA) in humans, that is CAA-related inflammation (CAA-RI) [237]. These 
findings indicate the potential role of target-specific immunity as well in the early events of 
AD pathogenesis, giving further potential relevance of altered 3-OH-L-KYN and 3-OH-ANA 
levels in the brain of AD patients. On the other hand, this potentially relevant feature further 
complicates the interpretation of the possible roles of these molecules in AD, especially of 3-
OH-L-KYN, a molecule that has pro-oxidant, antioxidant, as well as potent 
immunomodulatory features, all being of plausible relevance in AD. 
 
Quinolinic acid 
QUIN, which is produced by 3-hydroxyanthranilate 3,4-dioxygenase (HAAO), is a weak but 
specific competitive agonist of the NMDAR subgroup containing the GluN2A and GluN2B 
subunits, with low receptor affinity [238]. QUIN has been demonstrated to be a neurotoxic 
compound in several paradigms [5, 210]. On the one hand, it can cause glutamate 
excitotoxicity via the following mechanisms: it can directly activate NMDARs and, in 
addition to its receptorial effect, it is capable of modulating glutamate release and inhibiting 
the uptake of glutamate by astrocytes [239-241]. Accordingly, the hyperphosphorylation of 
tau proteins via the overactivation of NMDAR is augmented by QUIN, further contributing to 
glutamate excitotoxicity in AD [242]. On the other hand, QUIN has been demonstrated to be 
involved in ROS production and lipid peroxidation as well, in an NMDAR-dependent or -
independent manner, thereby further contributing to the pathogenesis of AD [243-246]. 
QUIN is capable of inducing NOS activity in astrocytes and neurons, generating ROS 
via the formation of QUIN-Fe2+ complexes, and reducing antioxidant defenses, thereby 
leading to oxidative stress and diminished mitochondrial function [247-252]. 
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As regards the expression of QUIN in AD brains, early studies demonstrated no alterations in 
various regions of the brain of AD patients [253-255]. However, Guillemin et al. reported 
increased QUIN immunoreactivity in neurons and glial cells in AD brains, with the microglial 
expression being the highest surrounding senile plaques, but also uniformly labeling 
neurofibrillary tangles, which is in line with the ability of QUIN to increase tau 
hyperphosphorylation [214, 215]. This increase of QUIN in AD plaques have been confirmed 
by further quantitative methods by the same group [256]. This increase corresponds to 
elevated QUIN levels observed in the plasma of AD patients correlating inversely with 
cognitive functions [234]. However, this finding as regards increased blood QUIN levels in 
AD could not be replicated by others from serum [232]. Likewise, no difference could be 
detected in the CSF levels of QUIN by multiple groups [255, 257]. Data regarding the 
potential of QUIN to contribute to IDO-mediated immunosuppression is contradictory [258-
260]. Contrastingly, QUIN has been shown to promote astrocytes to produce large amounts of 
the potent monocyte chemoattractant protein-1 (MCP-1), and has the ability to induce 
astroglial production of IL-1β (a key mediator of neuroinflammation in AD), and dose-
dependently promotes astroglial proliferation, dysfunction, or cell death [261-263]. Together 
with the data evidencing that QUIN is preferentially expressed in microglia/macrophages and 
also does so in AD brains, these data may indicate that QUIN does not only represent a direct 
link between microglial neuroinflammation and oxidative damage/NMDAR-mediated 
excitotoxicity/mitochondrial dysfunction as relevant pathogenic factors in AD, but it may 
serve as a direct mediator of a positive feedback loop in microglial neuroinflammation [214, 
226-229]. With regard to the therapeutic targeting of QUIN-related alterations in AD, the 
application of 4-chlorokynurenine (4-Cl-KYN), the BBB-penetrant pro-drug of the selective 
glycine site NMDAR antagonist, 7-Cl-kynurenic acid (7-Cl-KYNA), was demonstrated to 
ameliorate QUIN-induced hippocampal toxicity [264]. The explanation for this finding may 
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involve the powerful inhibition of QUIN synthesis by 4-chloro-3-hydroxyanthranilate, 
another metabolite of 4-Cl-KYN, in addition to the formation of 7-Cl-KYNA [265, 266]. 
 
Kynurenic acid 
KYNA is another product of the KYN pathway of TRP metabolism. It is produced by 
kynurenine aminotransferases (KATs) and can influence glutamatergic neurotransmission at 
several levels and have exerted neuroprotective effects in several paradigms [5, 202, 210, 267, 
268]. KYNA is capable of exerting a wide-spectrum of endogenous antagonistic effects at 
ionotropic excitatory amino acid receptors [269]. Its major action related to such receptors is 
mediated via the strychnine-insensitive glycine-binding site on the GluN1 subunit of the 
NMDAR [270]. However, the basal extracellular concentration of KYNA in rats (15–23 nM) 
is far below the required level, i.e., ~10–20 μM concentrations, to directly interfere with 
NMDAR functions under physiological concentrations [208, 271, 272]. Of note, KYNA has 
been demonstrated to have a dose-dependent dual action on AMPA receptors, as in low (nM 
to µM) concentrations, KYNA is capable of facilitating AMPA receptor responses with a 
potential positive effect on LTP, whereas in higher concentrations it has inhibitory effects, 
which may interfere with LTP formation and may be associated with cognitive dysfunctions 
[273, 274]. Though the most widely recognized and generally hypothesized neuroprotective 
mechanism of KYNA is linked to its anti-glutamatergic effects, predominantly on NMDARs, 
recent experimental findings associate KYNA with various additional actions counteracting 
processes relevant in mitochondrial dysfunction and neuroinflammation involved in AD. 
The connection between altered KYNA levels and mitochondrial dysfunction is 
represented by the following observations. 1) As a free radical scavenger, KYNA can be 
regarded as an endogenous neuroprotectant in conditions with mitochondrial 
dysfunction, where excessive free radical production is present as a general feature [275-
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277]. 2) Its potent NMDAR inhibitor functions can indirectly alleviate the downstream 
deleterious effects of excitotoxicity on mitochondrial function (i.e., by decreasing 
intracellular Ca2+ overload) [278]. 3) The expression/function of KATs has been 
reported to be downregulated in models/conditions with mitochondrial dysfunction [279, 
280]. 
The effects of KYNA with direct implications in neuroinflammation in AD include the 
inhibition of TNFα expression via an agonistic effect on orphan receptor GPR35 on 
monocytes, and more recently by increasing the expression of neprilysin, an Aβ-degrading 
metallopeptidase expressed by astrocytes and microglia, the proper function of which has 
been found to substantially influence the severity of AD-like phenotype in experimental 
models in vivo [277, 281-284]. Regarding the proposed Aβ-degrading effect, however, it is to 
be mentioned that a previous study did not found KYNA to be able to modulate Aβ 
aggregation in their experiments [285]. In terms of immunomodulation, although KYNA did 
not influence Aβ-induced cell death in BV-2 microglial cell culture, it exerted an anti-
inflammatory action by means of the reduction of the levels of proinflammatory cytokines 
TNFα and IL-6, and, intriguingly, decreasing the phagocytosis of Aβ [286]. As regards IL-6, 
another study likewise found a downregulation of this cytokine in stimulated mast cells [287]. 
However, a study on MCF-7 breast tumor cells reported the ability of KYNA to promote of 
IL-6 expression/secretion by activating aryl hydrocarbon receptor (AhR), which the authors 
discussed to potentially contribute to tumor camouflage by leading to a consequent increase in 
IDO expression in dendritic cells with various immunosuppressive downstream effects [288]. 
The relevance or presence of this mechanism in a neurodegenerative/neuroinflammatory 
setting in the brain, however, has not been established. 
With regard to post mortem analyses of the brains of AD patients, the levels of KYNA were 
found to be non-significantly elevated in the hippocampus with no apparent changes in the 
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activities of either KAT-I or KAT-II [231]. Consistently, no significant alterations in KYNA 
levels in various brain regions were detected by another group in AD brains [289]. However, 
increased KAT-I activity in the caudate nucleus and putamen (together with a non-significant 
alterations in KAT-II activity) with a consequent significant elevations in KYNA 
concentrations in the respective regions have been described [231]. The role and relevance of 
this phenomenon in the striatum are of question, but the presence of a compensatory 
mechanism against the pronounced degeneration of the corticostriatal pathway with increased 
glutamate binding in the striatum in AD may be a suitable explanation [290, 291]. The 
cellular distribution of the observed alterations in KAT activity and/or expression may have a 
special importance, because it was demonstrated that treatment of rats with sodium azide (an 
inhibitor of mitochondrial complex IV) altered the pattern of the expression of KAT-I in 
various relevant brain regions: the astroglial immunoreactivity was found to be decreased, 
whereas neurons started to express KAT-I [292]. With regard to the alterations of KYNA 
levels in human biological fluids with a possible biomarker value, decreased concentrations 
have been detected in the serum, plasma, and CSF of AD patients; however, recent studies 
have reported unaltered serum and CSF KYNA levels [232, 234, 257, 293, 294]. In one of 
these recent studies that did not find significant alteration in CSF KYNA level between AD 
patients and age-matched controls and revealed no associations between CSF KYNA level 
and cognitive dysfunctions in AD patients, CSF KYNA levels were, however, found to be 
significantly correlated with the AD-biomarker p-tau (hyperphosphorylated tau) and the 
inflammatory marker soluble intercellular adhesion molecule-1 [294]. Furthermore, a gender 
difference was also demonstrated in this study, i.e., female AD patients had significantly 
higher CSF KYNA levels compared to the males, a difference not revealed in the control 
group. Interestingly, however, increased levels of circulating immunoglobulin A (IgA) against 
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conjugated KYNA were detected in the serum of AD patients, adding to the spectrum of 
controversial findings in the field [233]. 
On the basis of the well-established contribution of glutamate excitotoxicity (including the 
elevation of hippocampal QUIN levels), mitochondrial dysfunction (including ROS 
accumulation), and neuroinflammation (including glial IDO activation) to AD pathogenesis, 
the accumulating data supports that KYNA has multiple potential beneficial actions that 
involve all these three major pathogenic domains. Indeed, the inclusion of KYNA during the 
preparation process of hippocampal slices from AβPPsw transgenic animals exerted an age-
dependent protective effect against the development of altered synaptic transmission, 
presumably by limiting the extent of excitotoxicity [295]. Furthermore, the systemic 
administration of L-KYN (the common precursor of KYNA, the probably neurotoxic 
metabolites 3-OH-L-KYN and anthranilic acid (ANA), and the ‘proglutamatergic’ excitotoxin 
QUIN) together with probenecid (an organic acid transporter inhibitor targeting the 
mechanisms eliminating KYNA from the brain) exerted protective effects against the 
intrahippocampal administration of Aβ25-35, with a significant improvement in spatial 
memory. This effect was most probably attributed to NMDAR inhibition, as demonstrated by 
comparable effect of the specific NMDAR inhibitor, MK-801 [296]. A possible way to 
enhance the bioavailability of KYNA may be achieved by its improved transport through the 
blood-brain barrier (BBB) via its pharmaceutical modulation [297]. Most recently, the 
neuroprotective effect of a novel BBB-permeable KYNA analog with multiple 
pharmacological actions relevant in AD pathogenesis, including NMDAR binding, free 
radical scavenging, and also interference with Aβ fibril evolution, has been reported in a 
Caenorhabditis elegans model of AD [298]. The potential 
neuroprotective/immunomodulatory features of KYNA relevant in AD highlight the 
importance of astrocytes in AD pathogenesis, as they lack functional KMO therefore 
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preferentially metabolizing L-KYN toward KYNA, and they readily expressed IDO in AD 
hippocampi [214, 228]. Interestingly, another KYNA analog, 5,7-dichlorokynurenic acid with 
a preferential action at the glycine-binding site of the NMDAR, was unable to recapitulate the 
protective effect of memantine, a partial antagonist at the NMDAR channel, on the abnormal 
hyperphosphorylation and accumulation of tau in organotypic cultures of rat hippocampal 
slices [299].  
Despite the promising experimental data, manipulations resulting in elevated levels of KYNA 
in the brain may inherently harbor effects associated with cognitive impairments and 
behavioral alterations [300-306]. Accordingly, knocking out one of its producing enzyme 
(KAT-II) resulted in the improvement of cognitive functions in mice [305]. Of note, 
achieving a selective inhibition of GluN2B subunit-containing extrasynaptic NMDARs may 
be a successful strategy in the amelioration of neurodegenerative processes [307]. Indeed, 
reaching an extracellular concentration that is capable of inhibiting the tonic extrasynaptic 
NMDAR currents and thereby reducing glutamate excitotoxicity in AD without impairing 
synaptic glutamatergic neurotransmission may yield a possible therapeutic option [308]. 
KYNA amides are synthesized by the amidation of KYNA at the carboxyl moiety and the 
resulting substances may preferentially act on GluN2B subunit-containing extrasynaptic 
NMDARs [209, 309]. Accordingly, one of the KYNA amide compounds synthesized by our 
group, N-(2-N,N-dimethylaminoethyl)-4-oxo-1H-quinoline-2-carboxamide hydrochloride 
exerted protective effects both in the N171-82Q transgenic mouse model of Huntington’s 
disease and the four-vessel occlusion model of cerebral ischemia in rats [310, 311]. At the 
dose capable of exerting these neuroprotective effects, the KYNA analog did not demonstrate 
any significant systemic side effects, i.e., it did not alter locomotor activity, working memory 
performance, and long-lasting, consolidated reference memory in contrast to the observed 
indirect side-effects following KYN administration [312-314]. These results are supported by 
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the findings that instead of decreasing LTP as it might be expected from its potential 
NMDAR antagonistic properties, it rather facilitated the potentiation of field excitatory 
postsynaptic potentials [315]. 
These data together strongly support the therapeutic potential of certain approaches related to 
the elevation of the levels of KYNA or its analogs in the brain in AD, with carefully keeping 
in mind the potential cognitive deleterious effects of the inhibition of synaptic NMDA/AMPA 
receptor-mediated currents during rational drug design. 
 
6. CONCLUSIONS 
Although more and more details are being revealed regarding the pathomechanism of AD, 
including mitochondrial dysfunction, glutamate excitotoxicity (Fig. 2), and 
neuroinflammation (Fig. 3), current therapeutic strategies are restricted only to few 
pharmaceutical agents. These three aspects of the pathomechanism certainly demonstrate 
relations to specific alterations in the KYN pathway of TRP metabolism (Fig. 2) [316-318]. 
Accordingly, the treatment of AD via the modulation of TRP metabolism appears to be a 
reasonable target of investigation; however, the complexity of the observed alterations and the 
seemingly narrow therapeutic window necessitate the development of sophisticated 
pharmaceutical approaches. 
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9. FIGURE CAPTIONS 
Figure 1. The schematic depiction of the kynurenine pathway of tryptophan metabolism. 
 
Figure 2. The possible implications of kynurenine pathway metabolites in mitochondrial 
dysfunction and glutamate excitotoxicity. 3-OH-ANA: 3-hydroxy-anthranilic acid, 3-OH-L-
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KYN: 3-hydroxy-L-kynurenine, cc.: concentration, KYNA: kynurenic acid, LTD: long-term 
depression, LTP: long-term potentiation, QUIN: quinolinic acid 
 
Figure 3. The possible implications of kynurenine pathway metabolites in neuroinflammation 
in AD. Aβ triggers IDO induction in microglia/macrophages and astrocytes, with consequent 
activation of the kynurenine pathway. Microglia/macrophages preferentially metabolize L-
KYN through the KMO branch, giving rise to 3-OH-ANA, 3-OH-L-KYN, and QUIN. 3-OH-
ANA and 3-OH-L-KYN are implicated in oxidative stress and suppression of target-specific 
immune response, and their exact role in AD pathogenesis is not well established. QUIN is a 
neurotoxic metabolite abundantly present in hallmark pathologies such as amyloid plaques 
and neurofibrillary tangles, and can contribute to AD pathology by promoting 
neurodegeneration, tau hyperphosphorylation, lipid peroxidation, astrocyte dysfunction, and 
monocyte recruitment. Astrocytes preferentially metabolize L-KYN through the transaminase 
branch, giving rise to KYNA. KYNA may act as an endogenous neuroprotectant due to its 
anti-excitotoxic, antioxidant, Aβ degradation-promoting, and anti-inflammatory properties, 
with the latter being attributable to its ability to downregulate TNFα and IL-6 production in 
microglia/macrophages. 3-OH-ANA: 3-hydroxy-anthranilic acid, 3-OH-L-KYN: 3-hydroxy-
L-kynurenine, Aβ: Amyloid-beta, IL-6: interleukin-6, KATs: kynurenine aminotransferases, 
KMO: kynurenine 3-monooxygenase, KYNA: kynurenic acid, IDO: indolamine 2,3-
dioxygenase, TNFα: tumor necrosis factor alpha QUIN: quinolinic acid 
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